FIGO 2018分期在局部晚期宫颈癌放化疗患者中的验证研究
中位随访33个月,116例复发。FIGO 2018分期各亚组3年无病生存率异质性明显,淋巴结阳性患者预后受原发肿瘤体积和淋巴结负荷影响,作者据此提出对TNM分期的修改建议。
要点
- FIGO 2018分期在淋巴结阳性患者中预后异质性明显。
- 有临床显著淋巴结病变者3年DFS低于无淋巴结病变者。
- 腹主动脉旁淋巴结≥3枚者DFS显著差于<3枚者。
核心结论
- FIGO 2018分期修改后淋巴结阳性患者预后异质性明显,受原发肿瘤和淋巴结体积影响,建议修改现有TNM分期以更稳健分类预后。
主要发现
- 185例(29.3%)有盆腔淋巴结病变,51例(8.2%)有腹主动脉旁淋巴结阳性。
- 中位随访33个月,116例(18.3%)复发。
- FIGO 2009分期IB、IIA、IIB、IIIA、IIIB、IVA的3年DFS分别为86%、91%、76%、57%、65%、61%。
- FIGO 2018再分期后IB、IIA、IIB、IIIA、IIIB、IIIC1、IIIC2、IVA的3年DFS分别为100%、93%、84%、53%、77%、74%、61%、61%。
临床怎么用
- 对局部晚期宫颈癌患者进行FIGO 2018分期时,应关注淋巴结受累数目及原发肿瘤体积对预后的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In 2018, the International Federation of Gynecology and Obstetrics (FIGO) proposed a new staging for cervical cancer. The present study was designed to reclassify patients with locally advanced cervix cancer and perform a comparative evaluation with FIGO 2009. METHODS AND MATERIALS: Patients with locally advanced cervical cancer (stage IB2-IVA) who had baseline cross-sectional imaging and received (chemo-) radiation and brachytherapy were included. Survival outcomes were analyzed according to FIGO 2009. Patients were then reclassified according to FIGO 2018, and TNM classification outcomes were analyzed. FIGO stage and known prognostic factors were included in univariate analysis, and multivariate analysis was performed to investigate the prognostic value of clinical stage. RESULTS: Six hundred thirty-two patients were included. Overall, 185 (29.3%) patients had pelvic adenopathy, and 51 (8.2%) had positive paraortic nodes. At a median follow-up of 33 months, 116 (18.3%) patients had recurrence. Three-year disease-free survival (DFS) according to FIGO 2009 for stage IB, IIA, IIB, IIIA, IIIB, and IVA was 86%, 91%, 76%, 57%, 65%, and 61%, respectively. The 3-year DFS after restaging according to FIGO 2018 for stage IB, IIA, IIB, IIIA, IIIB, IIIC1, IIIC2, and IVA was 100%, 93%, 84%, 53%, 77%, 74%, 61%, and 61%, respectively. Patients with clinically significant lymphadenopathy had inferior outcomes compared with node-negative patients (62.9% vs 77.8%; P = .002). Patients with ≥3 paraortic nodes had poorer DFS than patients with <3 paraortic lymphadenopathy (13.6% vs 56.3%; P = .001). Furthermore, patients with primary tumor volume >30 cm3 had worse 3-year DFS than those with primary tumor volume ≤30 cm3 (67.4% vs 78.5%; P = .002). CONCLUSIONS: FIGO 2018 modification is associated with heterogenous outcomes in node-positive patients that are affected by primary tumor and nodal volume. We propose a modification to the existing TNM staging system to allow more robust classification of outcomes.
引用
- Raut A, Chopra S, Mittal P, et al. FIGO Classification 2018: Validation Study in Patients With Locally Advanced Cervix Cancer Treated With Chemoradiation. Int J Radiat Oncol Biol Phys. 2020. PMID: 32681859. doi:10.1016/j.ijrobp.2020.07.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。